Concepts (217)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Evoked Potentials, Auditory, Brain Stem | 7 | 2022 | 11 | 1.640 |
Why?
|
| Auditory Perception | 5 | 2018 | 70 | 1.500 |
Why?
|
| Hearing Loss, Noise-Induced | 3 | 2022 | 7 | 1.500 |
Why?
|
| HIV Infections | 11 | 2026 | 2586 | 1.260 |
Why?
|
| Anura | 6 | 2021 | 34 | 1.250 |
Why?
|
| Deafness | 4 | 2023 | 7 | 1.200 |
Why?
|
| Sexually Transmitted Diseases | 3 | 2025 | 174 | 1.000 |
Why?
|
| Prisoners | 2 | 2025 | 102 | 1.000 |
Why?
|
| Homosexuality, Male | 6 | 2026 | 486 | 0.990 |
Why?
|
| Auditory Threshold | 5 | 2022 | 7 | 0.950 |
Why?
|
| Hearing Loss | 3 | 2020 | 16 | 0.940 |
Why?
|
| Noise | 4 | 2022 | 10 | 0.820 |
Why?
|
| Vocalization, Animal | 4 | 2017 | 55 | 0.680 |
Why?
|
| Substance-Related Disorders | 2 | 2025 | 830 | 0.640 |
Why?
|
| Physician Assistants | 3 | 2024 | 20 | 0.610 |
Why?
|
| Cochlear Nucleus | 1 | 2018 | 2 | 0.580 |
Why?
|
| Hyperkinesis | 1 | 2018 | 7 | 0.580 |
Why?
|
| Spiral Ganglion | 1 | 2018 | 6 | 0.580 |
Why?
|
| Diet | 5 | 2023 | 826 | 0.540 |
Why?
|
| Male | 29 | 2026 | 23409 | 0.530 |
Why?
|
| Sex Factors | 3 | 2017 | 1028 | 0.510 |
Why?
|
| Hearing | 5 | 2023 | 11 | 0.480 |
Why?
|
| Anti-HIV Agents | 4 | 2026 | 486 | 0.480 |
Why?
|
| Mice, Inbred CBA | 5 | 2022 | 42 | 0.470 |
Why?
|
| Behavior, Animal | 1 | 2018 | 373 | 0.470 |
Why?
|
| Peripheral Nervous System | 1 | 2015 | 14 | 0.450 |
Why?
|
| Acoustic Stimulation | 6 | 2022 | 78 | 0.440 |
Why?
|
| Siblings | 2 | 2024 | 22 | 0.420 |
Why?
|
| Female | 20 | 2026 | 24698 | 0.420 |
Why?
|
| Body Size | 1 | 2014 | 49 | 0.410 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2021 | 760 | 0.400 |
Why?
|
| Young Adult | 9 | 2026 | 5080 | 0.390 |
Why?
|
| Animals | 20 | 2023 | 16992 | 0.370 |
Why?
|
| Humans | 30 | 2026 | 43102 | 0.360 |
Why?
|
| Biomedical Research | 1 | 2017 | 502 | 0.360 |
Why?
|
| Los Angeles | 5 | 2026 | 394 | 0.350 |
Why?
|
| Hair Cells, Auditory | 3 | 2020 | 9 | 0.340 |
Why?
|
| Adult | 12 | 2026 | 13872 | 0.300 |
Why?
|
| Middle Aged | 11 | 2026 | 12222 | 0.280 |
Why?
|
| Leadership | 3 | 2023 | 86 | 0.270 |
Why?
|
| Mice | 7 | 2023 | 6644 | 0.250 |
Why?
|
| Peer Group | 2 | 2025 | 177 | 0.240 |
Why?
|
| Patient Compliance | 1 | 2026 | 233 | 0.210 |
Why?
|
| Cochlea | 2 | 2022 | 6 | 0.210 |
Why?
|
| Vestibular Diseases | 1 | 2023 | 3 | 0.210 |
Why?
|
| Hearing Loss, Sensorineural | 1 | 2023 | 10 | 0.210 |
Why?
|
| Hematologic Diseases | 1 | 2023 | 13 | 0.210 |
Why?
|
| Abnormalities, Multiple | 1 | 2023 | 38 | 0.210 |
Why?
|
| Face | 1 | 2023 | 40 | 0.200 |
Why?
|
| Nutrition Surveys | 2 | 2021 | 263 | 0.200 |
Why?
|
| Sexual Behavior | 3 | 2025 | 638 | 0.200 |
Why?
|
| Food | 1 | 2023 | 103 | 0.190 |
Why?
|
| Nutrition Assessment | 1 | 2023 | 80 | 0.190 |
Why?
|
| Faculty | 1 | 2023 | 105 | 0.180 |
Why?
|
| Sexual Partners | 2 | 2022 | 326 | 0.180 |
Why?
|
| Social Support | 1 | 2025 | 445 | 0.180 |
Why?
|
| Echolocation | 1 | 2021 | 3 | 0.180 |
Why?
|
| United States | 6 | 2024 | 5205 | 0.180 |
Why?
|
| Personal Satisfaction | 1 | 2022 | 76 | 0.170 |
Why?
|
| Chiroptera | 1 | 2021 | 25 | 0.170 |
Why?
|
| Psychoacoustics | 3 | 2020 | 5 | 0.170 |
Why?
|
| Physicians | 1 | 2023 | 188 | 0.170 |
Why?
|
| Animal Communication | 1 | 2021 | 7 | 0.170 |
Why?
|
| Education, Medical | 1 | 2022 | 118 | 0.170 |
Why?
|
| Continuity of Patient Care | 1 | 2022 | 120 | 0.170 |
Why?
|
| Mole Rats | 1 | 2020 | 5 | 0.170 |
Why?
|
| Aging | 3 | 2022 | 783 | 0.170 |
Why?
|
| Fatty Liver | 1 | 2021 | 77 | 0.160 |
Why?
|
| Post-Exposure Prophylaxis | 1 | 2020 | 12 | 0.160 |
Why?
|
| Sex Characteristics | 2 | 2020 | 258 | 0.160 |
Why?
|
| Central Nervous System Stimulants | 1 | 2022 | 180 | 0.160 |
Why?
|
| Health Knowledge, Attitudes, Practice | 3 | 2024 | 989 | 0.160 |
Why?
|
| Nerve Degeneration | 1 | 2020 | 111 | 0.160 |
Why?
|
| Cross-Sectional Studies | 3 | 2026 | 3156 | 0.160 |
Why?
|
| Species Specificity | 3 | 2015 | 286 | 0.160 |
Why?
|
| Disease Models, Animal | 2 | 2022 | 1596 | 0.150 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2024 | 497 | 0.150 |
Why?
|
| Neurons | 3 | 2017 | 1263 | 0.150 |
Why?
|
| Adaptation, Physiological | 1 | 2020 | 143 | 0.150 |
Why?
|
| Curcumin | 1 | 2020 | 118 | 0.150 |
Why?
|
| Hypertension | 1 | 2026 | 835 | 0.150 |
Why?
|
| Mexican Americans | 1 | 2021 | 226 | 0.150 |
Why?
|
| Thalamus | 1 | 2018 | 34 | 0.140 |
Why?
|
| Analgesics, Opioid | 2 | 2013 | 252 | 0.140 |
Why?
|
| Evolution, Molecular | 1 | 2020 | 307 | 0.140 |
Why?
|
| Visual Cortex | 1 | 2018 | 64 | 0.140 |
Why?
|
| Visual Perception | 1 | 2018 | 80 | 0.140 |
Why?
|
| Long-Term Potentiation | 1 | 2018 | 109 | 0.140 |
Why?
|
| Inferior Colliculi | 1 | 2017 | 4 | 0.130 |
Why?
|
| Nonlinear Dynamics | 1 | 2017 | 35 | 0.130 |
Why?
|
| Catechol O-Methyltransferase | 1 | 2017 | 18 | 0.130 |
Why?
|
| Minority Groups | 1 | 2022 | 690 | 0.130 |
Why?
|
| Catecholamines | 1 | 2017 | 45 | 0.130 |
Why?
|
| Exercise | 1 | 2023 | 692 | 0.130 |
Why?
|
| Cornea | 2 | 1988 | 70 | 0.130 |
Why?
|
| Reaction Time | 2 | 2014 | 157 | 0.120 |
Why?
|
| Mechanotransduction, Cellular | 1 | 2017 | 61 | 0.120 |
Why?
|
| Collagen | 2 | 1988 | 181 | 0.120 |
Why?
|
| Aged | 4 | 2026 | 8214 | 0.120 |
Why?
|
| Health Status Disparities | 1 | 2021 | 719 | 0.110 |
Why?
|
| Feedback, Physiological | 1 | 2014 | 32 | 0.110 |
Why?
|
| Tympanic Membrane | 1 | 2014 | 1 | 0.110 |
Why?
|
| Sound Localization | 1 | 2014 | 4 | 0.110 |
Why?
|
| Electrophysiology | 1 | 2014 | 138 | 0.100 |
Why?
|
| Caudate Nucleus | 1 | 2013 | 22 | 0.100 |
Why?
|
| Macaca fascicularis | 1 | 2013 | 65 | 0.100 |
Why?
|
| Receptors, Opioid, kappa | 2 | 2013 | 23 | 0.100 |
Why?
|
| Feasibility Studies | 2 | 2024 | 259 | 0.100 |
Why?
|
| Receptors, Opioid, mu | 2 | 2013 | 52 | 0.090 |
Why?
|
| Nucleus Accumbens | 1 | 2013 | 100 | 0.090 |
Why?
|
| Analysis of Variance | 1 | 2014 | 575 | 0.090 |
Why?
|
| Antineoplastic Agents | 1 | 2020 | 1019 | 0.090 |
Why?
|
| Educational Status | 2 | 2023 | 339 | 0.090 |
Why?
|
| Models, Biological | 1 | 2014 | 712 | 0.080 |
Why?
|
| Incidence | 2 | 2026 | 1078 | 0.080 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2013 | 587 | 0.080 |
Why?
|
| Research Design | 2 | 2023 | 385 | 0.070 |
Why?
|
| Keratoconus | 1 | 1988 | 18 | 0.070 |
Why?
|
| Injections | 1 | 2026 | 42 | 0.060 |
Why?
|
| Delayed-Action Preparations | 1 | 2026 | 74 | 0.060 |
Why?
|
| Opioid-Related Disorders | 1 | 2008 | 195 | 0.060 |
Why?
|
| Lung | 2 | 2021 | 492 | 0.050 |
Why?
|
| Child | 2 | 2023 | 3443 | 0.050 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 1 | 2023 | 8 | 0.050 |
Why?
|
| Causality | 1 | 2023 | 45 | 0.050 |
Why?
|
| Medication Adherence | 1 | 2026 | 182 | 0.050 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2023 | 31 | 0.050 |
Why?
|
| Salaries and Fringe Benefits | 1 | 2023 | 12 | 0.050 |
Why?
|
| Urban Population | 1 | 2026 | 374 | 0.050 |
Why?
|
| Computer Simulation | 1 | 2026 | 408 | 0.050 |
Why?
|
| Geriatric Assessment | 1 | 2023 | 66 | 0.050 |
Why?
|
| HIV | 1 | 2022 | 100 | 0.050 |
Why?
|
| Faculty, Medical | 1 | 2022 | 74 | 0.050 |
Why?
|
| Intention | 1 | 2023 | 108 | 0.050 |
Why?
|
| Food Supply | 1 | 2023 | 122 | 0.040 |
Why?
|
| Neoplasm Proteins | 1 | 2023 | 228 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2024 | 760 | 0.040 |
Why?
|
| Eating | 1 | 2023 | 167 | 0.040 |
Why?
|
| Benzeneacetamides | 2 | 2013 | 6 | 0.040 |
Why?
|
| Fentanyl | 2 | 2013 | 16 | 0.040 |
Why?
|
| Pyrrolidines | 2 | 2013 | 31 | 0.040 |
Why?
|
| Adolescent | 3 | 2022 | 6081 | 0.040 |
Why?
|
| Viral Load | 1 | 2022 | 348 | 0.040 |
Why?
|
| Africa | 1 | 2020 | 82 | 0.040 |
Why?
|
| Sirolimus | 1 | 2020 | 70 | 0.040 |
Why?
|
| Motivation | 1 | 2024 | 513 | 0.040 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 2020 | 159 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2023 | 549 | 0.040 |
Why?
|
| DNA-Binding Proteins | 1 | 2023 | 561 | 0.040 |
Why?
|
| Amino Acid Substitution | 1 | 2020 | 135 | 0.040 |
Why?
|
| Selection, Genetic | 1 | 2020 | 75 | 0.040 |
Why?
|
| Regression Analysis | 1 | 2021 | 490 | 0.040 |
Why?
|
| Cohort Studies | 1 | 2024 | 1759 | 0.040 |
Why?
|
| Neoplastic Stem Cells | 1 | 2020 | 99 | 0.040 |
Why?
|
| Unsafe Sex | 1 | 2020 | 162 | 0.040 |
Why?
|
| Sensory Deprivation | 1 | 2018 | 7 | 0.040 |
Why?
|
| Base Sequence | 1 | 2020 | 983 | 0.040 |
Why?
|
| Inhibitory Postsynaptic Potentials | 1 | 2018 | 12 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2020 | 299 | 0.040 |
Why?
|
| Excitatory Postsynaptic Potentials | 1 | 2018 | 80 | 0.040 |
Why?
|
| Interneurons | 1 | 2018 | 65 | 0.030 |
Why?
|
| Disease Progression | 1 | 2020 | 667 | 0.030 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 2018 | 135 | 0.030 |
Why?
|
| Transcription, Genetic | 1 | 2020 | 592 | 0.030 |
Why?
|
| Auditory Pathways | 1 | 2017 | 10 | 0.030 |
Why?
|
| Sexual Behavior, Animal | 1 | 2017 | 64 | 0.030 |
Why?
|
| Methylation | 1 | 2017 | 119 | 0.030 |
Why?
|
| Staining and Labeling | 2 | 1988 | 107 | 0.030 |
Why?
|
| Prevalence | 1 | 2021 | 1612 | 0.030 |
Why?
|
| Models, Neurological | 1 | 2017 | 136 | 0.030 |
Why?
|
| Depression | 1 | 2023 | 863 | 0.030 |
Why?
|
| Action Potentials | 1 | 2017 | 246 | 0.030 |
Why?
|
| Tubocurarine | 1 | 2014 | 3 | 0.030 |
Why?
|
| Neuromuscular Nondepolarizing Agents | 1 | 2014 | 3 | 0.030 |
Why?
|
| Immobilization | 1 | 2014 | 11 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2020 | 968 | 0.030 |
Why?
|
| MicroRNAs | 1 | 2020 | 518 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2020 | 1455 | 0.030 |
Why?
|
| Brain Stem | 1 | 2014 | 52 | 0.030 |
Why?
|
| Vibration | 1 | 2014 | 23 | 0.030 |
Why?
|
| Space Perception | 1 | 2014 | 35 | 0.030 |
Why?
|
| Pressure | 1 | 2014 | 50 | 0.030 |
Why?
|
| Restraint, Physical | 1 | 2013 | 22 | 0.030 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 2013 | 27 | 0.030 |
Why?
|
| Weight Gain | 1 | 2014 | 139 | 0.030 |
Why?
|
| Injections, Intravenous | 1 | 2013 | 67 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2020 | 2676 | 0.020 |
Why?
|
| Wakefulness | 1 | 2013 | 24 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2018 | 1869 | 0.020 |
Why?
|
| Risk Factors | 1 | 2021 | 3994 | 0.020 |
Why?
|
| Hydrocortisone | 1 | 2013 | 93 | 0.020 |
Why?
|
| Texas | 1 | 2014 | 457 | 0.020 |
Why?
|
| Stress, Physiological | 1 | 2013 | 172 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2020 | 2157 | 0.020 |
Why?
|
| Motor Activity | 1 | 2014 | 437 | 0.020 |
Why?
|
| Nerve Tissue Proteins | 1 | 2013 | 386 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 1081 | 0.020 |
Why?
|
| Sulfur | 1 | 1989 | 22 | 0.020 |
Why?
|
| Reinforcement Schedule | 1 | 2008 | 15 | 0.020 |
Why?
|
| Spironolactone | 1 | 1989 | 36 | 0.020 |
Why?
|
| Self Administration | 1 | 2008 | 69 | 0.020 |
Why?
|
| Drug Interactions | 1 | 2008 | 150 | 0.020 |
Why?
|
| Conditioning, Operant | 1 | 2008 | 90 | 0.020 |
Why?
|
| Macaca mulatta | 1 | 2008 | 139 | 0.020 |
Why?
|
| Phenazines | 1 | 1988 | 6 | 0.020 |
Why?
|
| Histocytochemistry | 1 | 1988 | 47 | 0.020 |
Why?
|
| Azo Compounds | 1 | 1988 | 17 | 0.020 |
Why?
|
| Hot Temperature | 1 | 2008 | 141 | 0.020 |
Why?
|
| Pain Measurement | 1 | 2008 | 183 | 0.020 |
Why?
|
| Fixatives | 1 | 1986 | 7 | 0.020 |
Why?
|
| Stress, Psychological | 1 | 2013 | 661 | 0.020 |
Why?
|
| Corneal Diseases | 1 | 1986 | 11 | 0.020 |
Why?
|
| Reference Values | 1 | 1986 | 211 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2008 | 1124 | 0.010 |
Why?
|
| Half-Life | 1 | 1989 | 63 | 0.000 |
Why?
|
| Biotransformation | 1 | 1989 | 69 | 0.000 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 1989 | 465 | 0.000 |
Why?
|